RT Journal Article
T1 Experience with the potassium binder patiromer in hyperkalaemia management in heart failure patients in real life.
A1 Esteban-Fernandez, Alberto
A1 Ortiz Cortes, Carolina
A1 Lopez-Fernandez, Silvia
A1 Recio Mayoral, Alejandro
A1 Camacho Jurado, Francisco Javier
A1 Gomez Otero, Ines
A1 Molina, Maria
A1 Almenar Bonet, Luis
A1 Lopez-Vilella, Raquel
K1 Heart failure
K1 Hyperkalaemia
K1 Patiromer
K1 Potassium binders
AB Hyperkalaemia (HK) is common in heart failure (HF) patients, related to renal dysfunction and medical treatment. It limits medical therapy optimization, which impacts prognosis. New potassium (K) binders help control HK, allowing better medical management of HF. A retrospective multicentre register included all outpatients with HF and HK (K ≥ 5.1 mEq/L) treated with patiromer according to current recommendations. We evaluated analytic and clinical parameters before starting the treatment and at 7, 30 and 90 days, as well as adverse events related to patiromer and treatment optimization. We included 74 patients (71.6% male) with a mean age of 70.8 years (SD 9.2). Sixty-seven patients (90.5%) presented HK in the previous year. Forty patients (54.1%) underwent down-titration of a renin-angiotensin-aldosterone inhibitor (RAASi) or a mineralocorticoid receptor antagonist (MRA), and 27 (36.5%) stopped any of them due to HK. Initial K was 5.5 mEq/L (SD 0.6), with a significantly reduction at 7 days (4.9 mEq/L (SD 0.8); P  In a real-life cohort of patients with HF, patiromer reduced and maintained K levels during 3 months of follow-up. The most common adverse events were hypomagnesaemia and gastrointestinal disturbances. Patiromer helps optimize medical treatment, increasing the percentage of patients treated with RAASi and MRA at target doses. At the end of follow-up, natriuretic peptides values and hospital visits were reduced, suggesting the benefit of optimizing HF medical treatment.
PB John Wiley & Sons Ltd.
YR 2022
FD 2022-05-08
LK http://hdl.handle.net/10668/21917
UL http://hdl.handle.net/10668/21917
LA en
NO Esteban-Fernández A, Ortiz Cortés C, López-Fernández S, Recio Mayoral A, Camacho Jurado FJ, Gómez Otero I, et al. Experience with the potassium binder patiromer in hyperkalaemia management in heart failure patients in real life. ESC Heart Fail. 2022 Oct;9(5):3071-3078.
DS RISalud
RD Jul 30, 2025